Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Objectives: To quantify the magnitude of altruism value as applied to a hypothetical new treatment for a rare, severe pediatric disease: Duchenne muscular dystrophy (DMD). Study Design ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Duchenne muscular dystrophy (DMD) is the most common type ... Because DMD can cause heart problems, it's important for your child to see a heart doctor, called a cardiologist, for checkups ...

Muscular dystrophy ... to treat Duchenne MD. It's only prescribed to people who have a confirmed mutation in the DMD gene. It delivers a protein to muscles in the skeleton, heart, and lungs ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.